Clinical trial
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients…
NCT00050336 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00050336 |
|---|---|
| Title | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) |
| Official title | A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | Lonafarnib (SARASAR) |
| Enrollment | 702 |
| Start date | Dec 1, 2002 |
| Primary completion | Feb 1, 2004 |
| Completion | Mar 1, 2004 |
| First posted | Dec 5, 2002 |
| Last update posted | Aug 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: